CN114617880B - Application of IOWH-032 in preparation of anti-coronavirus drugs and drugs - Google Patents
Application of IOWH-032 in preparation of anti-coronavirus drugs and drugs Download PDFInfo
- Publication number
- CN114617880B CN114617880B CN202011456111.5A CN202011456111A CN114617880B CN 114617880 B CN114617880 B CN 114617880B CN 202011456111 A CN202011456111 A CN 202011456111A CN 114617880 B CN114617880 B CN 114617880B
- Authority
- CN
- China
- Prior art keywords
- iowh
- coronavirus
- protease
- coronaviruses
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention belongs to the technical field of pharmaceutical chemistry, and particularly relates to application of IOWH-032 in preparation of medicines for resisting coronavirus infection. The IOWH-032 has a strong inhibition effect on the enzyme activity of the target main protease 3Clpro of coronaviruses, especially novel coronaviruses, and can be used for preparing medicaments for resisting coronaviruses, especially novel coronavirus infections.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical chemistry, and in particular relates to application of IOWH-032 in preparation of medicines for resisting coronavirus infection
Background
Coronaviruses belong to the single positive strand RNA virus, and the family of coronaviruses mainly includes the novel coronavirus (SARS-CoV-2), the SARS coronavirus (SARS-CoV), the middle east respiratory syndrome coronavirus (MERS-CoV), HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU. Coronaviruses often cause respiratory and intestinal diseases, neurological symptoms and myocarditis. Infection with these diseases severely affects the health of people. The recurrent attacks of coronaviruses suggest that humans are poorly informed of their studies and that the development of drugs for the treatment of new coronaviruses is urgent.
The main protease of coronaviruses, also called 3C-like protease (3 CLpro), is a hydrolase expressed on the 5' -terminal genome nsp5 of coronaviruses, the main function of which is to cleave at least 11 sites on the polyproteins pp1a and pp1ab, which after hydrolysis need to be processed into mature functional proteins; the 3C-like protease (3 CLpro) is a cysteine protease, recognizing sequences with Leu and Glin at the P2 and P1 positions, respectively. In addition, the substrate binding site of 3C-like protease (3 CLpro) is highly conserved and plays a key role in mediating viral replication and transcription, so that 3CL protease can be used as an ideal target for anti-coronavirus drug design screening.
IOWH-032 is a potent inhibitor of synthesis of extracellular cystic fibrosis transmembrane conductance regulator (CFTR), with an IC50 value of 1.01. Mu.M [1] in experiments based on T84 and CHO-CFTR cells. CFTR chloride channel is the primary driving force for diarrhea caused by enteropathogenic bacteria and is therefore an attractive drug target. CFTR plays an important role in transepithelial fluid homeostasis by controlling chloride ions in and out of cells, ultimately leading to intracellular and extracellular water exchange [1]. Here we demonstrate that IOWH-032 can inhibit the enzymatic activity of the main protease 3Clpro of coronaviruses, especially novel coronaviruses. Through looking at the related data, no related report on IOWH-032 as coronavirus main protease 3Clpro inhibitor is seen.
Disclosure of Invention
Aiming at the problem that related inflammatory diseases such as lung, respiratory tract and intestinal tract diseases, nervous system symptoms, myocarditis and the like caused by coronaviruses lack effective prevention and treatment medicines, the invention points out the application of IOWH-032 in preparing medicines for resisting coronavirus inflammation.
The invention aims to provide IOWH-032 serving as an inhibitor of coronavirus 3C-like protease (3 CLpro) and application thereof in preparing medicaments for preventing and/or treating novel coronavirus infection. The technology of the invention is to carry out drug design based on the three-dimensional structure of novel coronavirus 3CLpro, and carry out virtual screening on thousands of compounds including natural product library, clinical compound library and antiviral drug library, thus obtaining the compounds which can inhibit novel coronavirus 3 CLpro. Then, we used the commercial 3CLpro fluorescent probe construction method to perform enzyme activity test and to perform inhibitor screening.
Through the drug screening according to the scheme, the invention discovers that a class of compounds shown as the following < formula 1) has an inhibition effect on SARS-CoV-2 3CL protease:
the compound has obvious inhibiting effect on novel coronavirus 3C-like protease (3 CLpro), and IC 50 =6.664 μm. The compounds are shown to be effective in inhibiting the activity of novel coronavirus 3C-like proteases. Moreover, given the high similarity of coronavirus main proteases reported in the literature, we theorize that this class of compounds is also effective in inhibiting the activity of other coronavirus main proteases, especially for SARS-CoV, MERS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU. Preferably, it has an inhibitory effectIOWH-032 also includes various optical isomers, hydrates thereof and pharmaceutically acceptable salts thereof with acids. The compounds of formula I can be combined with pharmaceutically acceptable adjuvants to prepare medicaments for the treatment and prophylaxis of novel coronavirus infections. The auxiliary agents comprise diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants and synergists which are conventional in the pharmaceutical field. The medicine can be made into injection, tablet, pill, capsule, suspension or emulsion. The administration route can be oral, percutaneous, intravenous or intramuscular injection.
Drawings
FIG. 1 is a graph showing the trend of the fluorescence intensity of a substrate peptide with time under the metabolism of a 3C-like protease at various concentrations of the inhibitor IOWH-032 of example 1
FIG. 2 is a graph showing the inhibition of novel coronavirus 3C-like protease by inhibitor IOWH-032 of example 2.
Detailed Description
In order to more clearly illustrate the present invention, the following examples are set forth only to more clearly illustrate the invention, and are not to be construed as limiting the invention.
All procedures and steps and reaction conditions of the substrate, etc. are designed and carried out according to methods well known to those skilled in the art when the experiment is carried out.
In the examples below, we used inhibitor molecules, purchased from MCE (MedChemExpress) or other common commercial sources.
SARS-Cov-2 3C-like protease used in the present invention is purchased from CrystalO Biopharma, substrate Dabcyl-KTSAVLQ +.SGFRKM-E (Edans) -NH2 is purchased from GL biochem, and borax borate buffer is purchased from Raymond organism.
Preferably, SARS-Cov-2 3C-like protease (concentration is 0.1 mg/mL), substrate peptide Dabcyl-KTSAVLQ ∈SGFRKM-E (Edans) -NH2 (concentration is 0.1mM-5 mM), borax borate buffer (pH=5-8) at a concentration of 10-100 mmol/L.
The invention needs to use a fluorescence enzyme-labeled instrument for fluorescence detection.
Example 1: determination of SARS-Cov-2 3C-like protease inhibitory Activity by IOWH-032
The specific implementation process is as follows:
1) Both SARS-Cov-2 3C-like protease and substrate peptide stock solutions were stored in a-80℃refrigerator;
2) Melting SARS-Cov-2 3C-like protease (concentration of 0.1 mg/mL) in a cryoprotectant (-4-4deg.C) at room temperature, diluting 1 μl into 98 μl borax borate buffer (pH=7.4), and adding into detection plate;
3) Adding 1 μl of inhibitor (IOWH-032, concentrations of 0,0.025mM,0.125mM,0.25mM,0.5mM,1mM, and 2.5 mM) to the solution obtained in step (2);
4) Adding 1 mu L of substrate peptide (0.5 mM) with the same concentration into the solution obtained in the step (3), incubating at 37 ℃ by using a fluorescence microplate reader, monitoring fluorescence emission value at 496nm by using the fluorescence microplate reader under 342nm excitation, and detecting at the same time when incubating, wherein each 1 minute is taken;
5) The effect of the slow increase in fluorescence intensity of the substrate peptide over time in the presence of various concentrations of inhibitor in enzyme metabolism is shown in FIG. 1 below, which shows that the increase in fluorescence of the substrate peptide in enzyme metabolism can be inhibited by inhibitor IOWH-032, and that this inhibition increases with increasing inhibitor concentration.
Example 2: determination of the ability of IOWH-032 to inhibit SARS-Cov-2 3C-like protease
The specific implementation process is as follows:
1) Both SARS-Cov-2 3C-like protease and substrate peptide stock solutions were stored in a-80℃refrigerator;
2) Melting SARS-Cov-2 3C-like protease (concentration of 0.1 mg/mL) in a cryoprotectant (-4-4deg.C) at room temperature, diluting 1 μl into 98 μl borax borate buffer (pH=7.4), and adding into detection plate;
3) Adding 1 μl of inhibitor (IOWH-032, concentrations of 0,0.025mM,0.125mM,0.25mM,0.5mM,1mM, and 2.5 mM) to the solution obtained in step (2);
4) Adding 1 mu L of substrate peptide (0.5 mM) with the same concentration into the solution obtained in the step (3), incubating at 37 ℃ by using a fluorescence microplate reader, monitoring fluorescence emission value at 496nm by using the fluorescence microplate reader, and incubating for 1h while detecting;
5) Fluorescence emission values at 496nm were counted for 342nm excitation before and after incubation of each group. Taking the fluorescence change value before and after incubation of the control group (inhibitor concentration 0 group) as 100, the residual activity value (residual activity) was obtained by comparing the fluorescence change value before and after incubation of the different inhibition groups. The IC of the inhibitor was obtained by plotting the logarithmic value of the inhibitor concentration (logC (Inhibitor)) on the abscissa and the corresponding residual activity value (Residual Activity) on the ordinate using GraphPad Prism6 software, the results being shown in FIG. 2 50 Values. Table 1 lists the activity data of compound 1 against SARS-Cov-2 3CLpro inhibition. IC (integrated circuit) 50 The formula for the calculation is y=100/(1+10 ((X-LogIC 50))), where Y represents the remaining activity fraction, X represents the usual logarithm of the concentration of inhibitor compound, Λ refers to the power algorithm. FIG. 2 is a graph showing the ratio of various inhibitor concentrations to the inhibition of enzyme activity, and the inhibition capacity of the compound can be obtained, expressed as the concentration of the inhibitor when the inhibition of enzyme activity is half.
Table 1: IOWH-032 structure and IC for inhibiting novel coronavirus 3C-like protease (3 CLpro) 50 Value of
It can be seen that the above compounds have very obvious inhibitory effect on novel coronavirus 3C-like protease, and IC 50 A value of 6.664. Mu.M indicates that IOWH-032 is effective in inhibiting the activity of novel coronavirus 3C-like protease. Furthermore, based on sequence analysis, coronavirus 3C-like proteases have a high similarity, and therefore, such compounds are also capable of effectively inhibiting the activity of other coronavirus 3C-like proteases, especially for SARS-CoV, MERS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1.
In addition, examples 1-2 were performed on the following compounds having a structure similar to IOWH-032 (the procedure and conditions were the same as in the above examples, except that the following compounds were used in place of the inhibitors, respectively), and were found to have no inhibition of the novel coronavirus 3C-like protease.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011456111.5A CN114617880B (en) | 2020-12-10 | 2020-12-10 | Application of IOWH-032 in preparation of anti-coronavirus drugs and drugs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011456111.5A CN114617880B (en) | 2020-12-10 | 2020-12-10 | Application of IOWH-032 in preparation of anti-coronavirus drugs and drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114617880A CN114617880A (en) | 2022-06-14 |
CN114617880B true CN114617880B (en) | 2023-06-06 |
Family
ID=81895133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011456111.5A Active CN114617880B (en) | 2020-12-10 | 2020-12-10 | Application of IOWH-032 in preparation of anti-coronavirus drugs and drugs |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114617880B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116036277B (en) * | 2022-07-19 | 2023-10-31 | 广州国家实验室 | Application of chloride ion in preventing and treating diseases caused by coronavirus |
CN115869306B (en) * | 2022-12-23 | 2024-03-19 | 华中科技大学协和深圳医院 | Application of IOWH-032 in preparation of medicine for resisting gram-positive bacterial infection |
-
2020
- 2020-12-10 CN CN202011456111.5A patent/CN114617880B/en active Active
Non-Patent Citations (1)
Title |
---|
Developing novel antisecretory drugs to treat infectious diarrhea;Eugenio L de Hostos;《Future Med. Chem.》;20111231;第1317-1325页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114617880A (en) | 2022-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yuan et al. | Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters | |
CN114617880B (en) | Application of IOWH-032 in preparation of anti-coronavirus drugs and drugs | |
Chiou et al. | The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease | |
CN111402968B (en) | New application of kaempferol in COVID-19 virus based on molecular simulation | |
WO2021175295A1 (en) | Application of myricetin compound in preparation of drugs for prevention and treatment of novel coronavirus pneumonia | |
Zhang et al. | Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro) | |
CN114469937B (en) | Application of PF-05231023 in preparation of anti-coronavirus infection medicines | |
WO2021164689A1 (en) | Application of nelfinavir in preparation of drug for preventing and treating novel coronavirus pneumonia | |
CN112137991A (en) | Application of diselenide compound as coronavirus 3C-like protease inhibitor, inhibitor and medicine | |
CN114617883B (en) | Application of fiboflapon in preparation of anti-coronavirus drugs and drugs | |
CN114617884B (en) | Application of PFK-158 in preparation of anti-coronavirus medicament and medicament | |
CN115737632B (en) | Application of LSD1 inhibitor in acute myelogenous leukemia resisting medicine | |
CN114246850A (en) | Application of p-benzoquinone or derivatives thereof in preparation of anti-coronavirus medicines and medicines | |
CN112156084A (en) | Application of diselenide compound as coronavirus papaya protease inhibitor, inhibitor and medicine | |
CN114515281B (en) | Application of Crystal Violet in preparation of anti-coronavirus infection medicine | |
CN114515282B (en) | Application of Sorbic acid in preparation of anti-coronavirus infection drugs | |
CN114617861B (en) | Application of TPI-1 and derivatives thereof in preparation of anti-coronavirus drugs and drugs | |
CN114617895A (en) | Application of tannic acid in preparing anti-coronavirus medicine and medicine | |
CN114432280A (en) | Application of Bronopol in preparation of anti-coronavirus infection medicine | |
TW202207909A (en) | Use of disulfiram for treating infection of sars-cov-2 | |
CN114469914B (en) | Application of phenelzine in preparation of coronavirus papain-like protease inhibitor | |
CN114515286A (en) | Application of Octenidine in preparation of anti-coronavirus infection medicine | |
CN114504583A (en) | Application of Mitoquinone in preparation of anti-coronavirus infection medicine | |
CN114246855A (en) | Application of Eflorhithine in preparation of anti-coronavirus infection medicine and medicine | |
CN114617862A (en) | Application of Vilanterol in preparation of anti-coronavirus medicines and medicines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |